Avenacy intros generic Zometa
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched zoledronic acid injection, which is a generic of Novartis’ Zometa.
Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard antineoplastic therapy.
Avenacy's zoledronic acid injection is available as a 4 mg/5 ml (0.8 mg per ml) single-dose vial.
[Read more: Avenacy intros generic Reglan]
Avenacy said that the medication will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.
Zoledronic acid injection had a market value of approximately $11.4 million for the 12 months ending in September 2024, per IQVIA.
[Read more: Avenacy releases magnesium sulfate in water for injection]